2019
Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*
Foss FM, Parker TL, Girardi M, Li A. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*. Leukemia & Lymphoma 2019, 60: 2927-2930. PMID: 31119966, DOI: 10.1080/10428194.2019.1612061.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaIncidence of mucositisAddition of leucovorinSkin reactionsLeucovorin administrationMucositis incidenceMucositis occurrenceDisease stabilizationAdverse eventsClinical responseCTCL patientsPoor prognosisLeucovorinMucositisPatientsResponse rateLymphomaPralatrexateIncidenceEfficacyPrognosisDosingAdministration
2012
Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma
Parker T, Barbarotta L, Girardi M, Foss F. Cutaneous Toxicity Associated with Pralatrexate in Cutaneous and Peripheral T-Cell Lymphoma. Blood 2012, 120: 3660. DOI: 10.1182/blood.v120.21.3660.3660.Peer-Reviewed Original ResearchPeripheral T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaRefractory cutaneous T-cell lymphomaRefractory peripheral T-cell lymphomaCutaneous toxicityMajority of patientsAdverse eventsMedian ageSkin flareMedian numberLow doseDiagnosis of PTCLCommon adverse eventsSpeakers bureauOff-label useIntravenous antibioticsCTCL patientsFirst doseToxic erythemaDose escalationCTCL lesionsMoist desquamationRetrospective reviewSkin breakdown
2011
Characterization of the DNA Copy-Number Genome in the Blood of Cutaneous T-Cell Lymphoma Patients
Lin WM, Lewis JM, Filler RB, Modi BG, Carlson KR, Reddy S, Thornberg A, Saksena G, Umlauf S, Oberholzer PA, Karpova M, Getz G, Mane S, Garraway LA, Dummer R, Berger CL, Edelson RL, Girardi M. Characterization of the DNA Copy-Number Genome in the Blood of Cutaneous T-Cell Lymphoma Patients. Journal Of Investigative Dermatology 2011, 132: 188-197. PMID: 21881587, PMCID: PMC3841973, DOI: 10.1038/jid.2011.254.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaBlood involvementLeukemic cutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsT-cell lymphoma patientsNormal CD4 countPeripheral blood isolatesT-cell lymphomaCTCL cell linesPotential future therapeutic developmentsT-cell malignanciesFuture therapeutic developmentSignificant copy number alterationsCD4 countSpectrum of stagesCTCL patientsSézary syndromeLymph nodesLymphoma patientsHodgkin's lymphomaPeripheral bloodBlood isolatesCutaneous patchCTCL samplesPatientsHigh-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade
Kießling M, Oberholzer PA, Mondal C, Karpova MB, Zipser MC, Lin WM, Girardi M, MacConaill LE, Kehoe SM, Hatton C, French LE, Garraway LA, Polier G, Süss D, Klemke CD, Krammer PH, Gülow K, Dummer R. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. Blood 2011, 117: 2433-2440. PMID: 21209378, PMCID: PMC3952811, DOI: 10.1182/blood-2010-09-305128.Peer-Reviewed Original ResearchMeSH KeywordsBiopsyHigh-Throughput Screening AssaysHumansLymphoma, T-Cell, CutaneousMitogen-Activated Protein Kinase KinasesMutationMycosis FungoidesNeoplasm StagingProtein Kinase InhibitorsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Raf KinasesRas ProteinsSezary SyndromeSignal TransductionConceptsCutaneous T-cell lymphomaStage IV patientsHUT78 cellsIV patientsPleomorphic cutaneous T-cell lymphomaHigh-throughput mutation profilingMEK inhibitorsCTCL cell line Hut78T-cell lymphomaRAS/RAF/MEKCTCL cell linesOncogenic mutationsCommon oncogenic mutationsCTCL patientsOverall survivalSézary syndromeMycosis fungoidesBiopsy specimensPatients profitPreclinical resultsMEK inhibitor U0126NRAS mutationsLymphoid cellsCTCL samplesRAS mutations
2006
Transimmunization for cutaneous T cell lymphoma: A phase I study
Girardi M, Berger CL, Wilson LD, Christensen IR, Thompson KR, Glusac EJ, Edelson RL. Transimmunization for cutaneous T cell lymphoma: A phase I study. Leukemia & Lymphoma 2006, 47: 1495-1503. PMID: 16966259, DOI: 10.1080/10428190600581419.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaT-cell lymphomaCTCL patientsCell lymphomaMalignant cellsCD8 T cell poolPhase I clinical studyT cell poolSignificant mean reductionElectron beam therapyInfiltrative lesionsClinical studiesDendritic antigenBlood monocytesTransimmunizationMean reductionTumor loadingPatientsMonoclonal antibodiesMalignant leukocytesMinimal toxicityBeam therapyPhase ICell poolVivo contact